EURneffy® nasal adrenaline spray approved by MHRA: first needle-free option for anaphylaxis treatment in the UK

The UK medicines regulator (MHRA) has approved EURneffy®, the country’s first needle-free adrenaline nasal spray for the emergency treatment of serious allergic reactions (anaphylaxis) in adults and children weighing 30kg or more. This new option is expected to become available towards the end of 2025, giving people at risk of life-threatening allergies a new way to carry life-saving medication.

What is EURneffy? 

EURneffy is the first adrenaline nasal spray approved in the UK to treat anaphylaxis, a serious allergic reaction that can occur within minutes of exposure to allergens such as foods, insect stings, or medications. Anaphylaxis causes life-threatening symptoms like breathing difficulties, swelling of the airways, and dangerously low blood pressure, all of which require immediate treatment with adrenaline.

Until now, the only way patients could self-administer adrenaline during anaphylaxis has been with adrenaline auto-injectors (AAIs) — portable devices that inject the medicine into the thigh using a needle. 

The EURneffy 2mg nasal spray provides an alternative, by delivering adrenaline directly into the nose. It has been approved for use in adults and children who weigh 30kg (66 pounds) or more. This new option may make it easier for some people to treat anaphylaxis without delay, especially those who are uncomfortable with needles.

How does EURneffy work?

Each EURneffy device contains one ready-to-use 2 mg dose of adrenaline, and works as follows:

1. Insert the tip into one nostril.
2. Press the plunger to release the full dose of adrenaline.

The medicine is absorbed through the lining of the nose and quickly enters the bloodstream—even if the nose is blocked by a cold or allergy. Once absorbed, adrenaline:

• Narrows blood vessels to raise low blood pressure
• Relaxes airway muscles to ease breathing
• Reduces swelling and hives caused by the allergic reaction

As with AAIs, patients should always carry two devices in case a second dose is needed. Training and a clear Patient Information Leaflet will be provided with any prescription.

Why is this approval important?

During anaphylaxis, giving adrenaline quickly is crucial to prevent serious complications. However, some people hesitate or delay using an AAI due to fear of needles, uncertainty about how to use the device, or concerns about needing to go to hospital afterwards, as current guidance recommends.

EURneffy offers a needle-free alternative that may reduce this hesitation and support faster treatment when every second counts. Its compact, lightweight design may also make it more convenient to carry, encouraging people to keep two doses with them at all times, as recommended.

By addressing both psychological and practical barriers, EURneffy could help more individuals access timely adrenaline treatment in an emergency.

What does this mean for people with allergies?

While EURneffy is expected to become available in the UK in late 2025, how quickly people can access it will depend on final regulatory steps, arrangements for pricing and supply, and readiness among healthcare professionals. It won’t be available straight away, and those who currently use AAIs will not be automatically switched. Instead, once EURneffy is available, healthcare professionals will work with each patient to decide whether a nasal spray, an injector, or both are most appropriate.

A lower 1 mg dose of EURneffy, suitable for children weighing 15 to 30 kg (33 to 66 pounds), has already been approved in the US and is under review in Europe, suggesting a UK launch of the children’s version is likely to follow in 2026.

For now, the approval of EURneffy marks an important new choice in anaphylaxis care, with the potential to help more people access timely treatment during life-threatening allergic reactions.

Staying prepared

Those at risk of anaphylaxis are advised to:

• Always carry two of your prescribed adrenaline devices.
• Ensure friends, family or caregivers know how to assist in an emergency.
• Familiarise yourself with the instructions for your device.
• Report any concerns or side effects to your GP, pharmacist or the MHRA Yellow Card scheme.

For guidance on recognising and responding to anaphylaxis, visit the page: What is Anaphylaxis

Read the MHRA press release here.